Clinical proteomics: Revolutionizing disease detection and patient tailoring therapy

被引:71
作者
Petricoin, E
Wulfkuhle, J
Espina, V
Liotta, LA
机构
[1] US FDA, NCI FDA Clin Proteom Program, Off Cell & Gene Therapy, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA
[2] NCI, NCI FDA Clin Proteom Program, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
关键词
proteomics; pharmacoproteomics; patterns; mass spectrometry; protein microarrays;
D O I
10.1021/pr049972m
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The evolving discipline of Clinical Proteomics is more than simply describing and enumerating the systematic changes in the protein constituency of a cell, or just generating lists of proteins that increase or decrease in expression as a cause or consequence of disease. Clinical applications of proteomics involve the use of proteomic technologies at the bedside with the ultimate goal to characterize the information flow through the intra- and extracellular molecular protein networks that interconnect organ and circulatory systems together. These networks are both new targets for therapeutics themselves as well as underpin the dynamic changes that give rise to cascades of new diagnostic biomarkers. The analysis of human cancer can be used as a model for how clinical proteomics is having an impact at the bedside for early detection, rational therapeutic targeting, and patient-tailored therapy.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 86 条
  • [41] Li JJ, 2000, ELECTROPHORESIS, V21, P198, DOI 10.1002/(SICI)1522-2683(20000101)21:1<198::AID-ELPS198>3.0.CO
  • [42] 2-V
  • [43] Li JN, 2002, CLIN CHEM, V48, P1296
  • [44] Molecular profiling of human cancer
    Liotta, L
    Petricoin, E
    [J]. NATURE REVIEWS GENETICS, 2000, 1 (01) : 48 - 56
  • [45] The microenvironment of the tumour-host interface
    Liotta, LA
    Kohn, EC
    [J]. NATURE, 2001, 411 (6835) : 375 - 379
  • [46] Written in blood
    Liotta, LA
    Ferrari, M
    Petricoin, E
    [J]. NATURE, 2003, 425 (6961) : 905 - 905
  • [47] Protein microarrays: Meeting analytical challenges for clinical applications
    Liotta, LA
    Espina, V
    Mehta, AI
    Calvert, V
    Rosenblatt, K
    Geho, D
    Munson, PJ
    Young, L
    Wulfkuhle, J
    Petricoin, EF
    [J]. CANCER CELL, 2003, 3 (04) : 317 - 325
  • [48] Clinical proteomics - Personalized molecular medicine
    Liotta, LA
    Kohn, EC
    Petricoin, EF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (18): : 2211 - 2214
  • [49] MacBeath G, 2001, NAT BIOTECHNOL, V19, P828, DOI 10.1038/nbt0901-828
  • [50] Mehta AI, 2003, DIS MARKERS, V19, P1